Abstract
Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged
| Original language | English (US) |
|---|---|
| Pages (from-to) | 379-384 |
| Number of pages | 6 |
| Journal | Annals of the Rheumatic Diseases |
| Volume | 65 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2006 |
| Externally published | Yes |
ASJC Scopus subject areas
- Rheumatology
- Immunology
Fingerprint
Dive into the research topics of 'Long term safety of etanercept in elderly subjects with rheumatic diseases'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS